TITLE

Enfuvirtide Antiviral Activity despite Rebound Viremia and Resistance Mutations: Fitness Tampering or a Case of Persistent Braking on Entering?

AUTHOR(S)
Morse, Caryn; Maldarelli, Frank
PUB. DATE
February 2007
SOURCE
Journal of Infectious Diseases;2/1/2007, Vol. 195 Issue 3, p318
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article comments on the therapeutic regimens including enfuvirtide to treat highly drug-resistant HIV-1. Enfuvirtide, the first of a new class of antiretrovirals, targets membrane fusion, an essential energy-requiring step in HIV infection. The clinical efficacy of enfuvirtide was demonstrated in multiple studies, which showed its superiority with an optimized antiretroviral background over optimized background alone in highly treatment-experienced patients.
ACCESSION #
23819738

 

Related Articles

  • Bicistronic retroviral vectors for combining myeloprotection with cell-surface marking. Hildinger, M; Schilz, A; Eckert, H-G; Bohn, W; Fehse, B; Zander, A R; Ostertag, W; Baum, C // Gene Therapy;Jul99, Vol. 6 Issue 7, p1222 

    We have developed a retroviral vector coexpressing the multidrug-resistance 1 (MDR1) cDNA for inducing cancer drug resistance and the truncated version of the low-affinity nerve growth factor receptor (ΔLNGFR) for cell-surface marking of transduced cells. The vector is based on the FMEV...

  • Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment Interruptions. Metzner, Karin J.; Bonhoeffer, Sebastian; Fischer, Marek; Karanicolas, Rose; Allers, Kristina; Joos, Beda; Weber, Rainer; Hirschel, Bernard; Kostrikis, Leondios G.; Günthard, Huldrych F. // Journal of Infectious Diseases;11/15/2003, Vol. 188 Issue 10, p1433 

    Examines the emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. Administration of anti-retroviral therapy to research subjects under a four cycles of two-week structured treatment...

  • Clinical Pharmacology of Gatifloxacin, a New Fluoroquinolone. Grasela, Dennis M. // Clinical Infectious Diseases;8/1/2000 Supplement 2, Vol. 31, pS51 

    Discusses the clinical pharmacology of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone that is active against a broad spectrum of pathogens including antibiotic-resistant Streptococcus pneumoniae. High oral bioavailability; Bioequivalent and interchangeable oral and intravenous...

  • Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Barber, Tristan J.; Harrison, Linda; Asboe, David; Williams, Ian; Kirk, Stuart; Gilson, Richard; Bansi, Loveleen; Pillay, Deenan; Dunn, David // Journal of Antimicrobial Chemotherapy (JAC);Apr2012, Vol. 67 Issue 4, p995 

    Background Selection of protease mutations on antiretroviral therapy (ART) including a ritonavir-boosted protease inhibitor (PI) has been reported infrequently. Scarce data exist from long-term cohorts on resistance incidence or mutational patterns emerging to different PIs. Methods We studied...

  • A Paradigm Shift to Prevent HIV Drug Resistance. Bangsberg, David R. // PLoS Medicine;May2008, Vol. 5 Issue 5, pe111 

    David Bangsberg discusses a new observational cohort study in nine countries in southern Africa that compares CD4 counts versus adherence to antiretroviral drugs for predicting virologic failure.

  • Into the great unknown -- treating drug-resistant TB and HIV. Conradie, Francesca // CME: Continuing Medical Education;Oct2011, Vol. 29 Issue 10, p427 

    The article focuses on efforts and progress in managing drug-resistant tuberculosis (TB) and HIV in South Africa. The South African government started the National HIV Counselling and Testing Campaign in April 2010, which obliges healthcare providers to offer HIV testing to TB patients. The...

  • Prevalence of Genotypic Resistance in Untreated HIV Patients in Spain. Eiros, J. M.; Labayru, C.; Hernández, B.; Ortega, M.; Bachiller, P.; de Lejarazu, R. Ortiz // European Journal of Clinical Microbiology & Infectious Diseases;Apr2002, Vol. 21 Issue 4, p310 

    The aims of this retrospective study were to assess the prevalence of primary genotypic resistance to antiretroviral drugs in untreated HIV patients in Spain using the line probe assay and to determine its possible relationship to several epidemiological variables. The global prevalence of...

  • Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. Bannister, Wendy P.; Cozzi-Lepri, Alessandro; Kjær, Jesper; Clotet, Bonaventura; Lazzarin, Adriano; Viard, Jean-Paul; Kronborg, Gitte; Duiculescu, Dan; Beniowski, Marek; Machala, Ladislav; Phillips, Andrew // Journal of Antimicrobial Chemotherapy (JAC);Apr2011, Vol. 66 Issue 4, p901 

    Objectives Estimating the prevalence of accumulated HIV drug resistance in patients receiving antiretroviral therapy (ART) is difficult due to lack of resistance testing at all occasions of virological failure and in patients with undetectable viral load. A method to estimate this for 6498...

  • Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study:1999-2008. Buchacz, Kate; Baker, Rose; Ward, Douglas J.; Palella, Frank J.; Chmiel, Joan S.; Young, Benjamin; Yangco, Bienvenido G.; Novak, Richard M.; Brooks, John T. // AIDS Research & Treatment;2012, p1 

    Background. Little is known about temporal trends in frequencies of clinically relevant ARV resistance mutations in HIV strains from U.S. patients undergoing genotypic testing (GT) in routine HIV care. Methods. We analyzed cumulative frequency of HIV resistance among patients in the HIV...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics